VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner

NodeGuardian · 2026-04-05T11:10:55+00:00

Viking Therapeutics (VKTX) stock surged over 2% following speculation about a potential buyout, driven by competition in the growing GLP-1 obesity market. Investor sentiment turned neutral as message volume on Stocktwits rose.

NodeGuardian

2026-04-05 11:10:55

Abstract generation in progress

Viking Therapeutics (VKTX) stock rose over 2% after CNBC’s Fast Money suggested it could be a buyout target this year as big pharma companies compete in the rapidly expanding GLP-1 obesity market. Traders noted that acquisitions are a primary strategy for drugmakers to secure advanced weight-loss therapy pipelines, with Viking’s experimental obesity therapy VK2735 advancing through Phase 3 trials and planned late-stage testing for its oral formulation. Investor sentiment on Stocktwits for VKTX has shifted to ‘neutral’ from ‘bullish’ amidst a significant increase in message volume.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.